Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma

28 Apr 2017

Abstract excerpt

Oncogenic “driver” mutations are theoretically attractive targets for the immunotherapy of lymphoid cancers, yet the proportion that can be recognized by T cells remains poorly defined. To address this issue without any confounding effects of the patient's immune system, we assessed T cells from 19 healthy donors for recognition of three common driver mutations in lymphoma: MYD88L265P, EZH2Y641F, and EZH2Y641N....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28811957
DOI: 10.1080/2162402x.2017.1321184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphomaPMID 28811957Read ↗

Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.Semantic proximity Read ↗

Genome-wide Screens Identify Lineage- and Tumor Specific-Genes Modulating MHC-I and MHC-II Immunosurveillance in Human LymphomasSemantic proximity Read ↗

Immunogenicity of non-canonical HLA-I tumor ligands identified through proteogenomicsSemantic proximity Read ↗

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapySemantic proximity Read ↗

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells.Semantic proximity Read ↗

A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignanciesSemantic proximity Read ↗

It's a long way to the top (if you want to personalize immunotherapy).Semantic proximity Read ↗

Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis.Semantic proximity Read ↗

Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyondSemantic proximity Read ↗

The HLA Ligand Atlas - A resource of natural HLA ligands presented on benign tissuesSemantic proximity Read ↗

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.Semantic proximity Read ↗

IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHC CII complexesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.